Advancing Tomorrow’s Life Sciences

The time is now for life sciences. Unmet needs in modern therapeutic development paired with technology breakthroughs are creating enormous opportunity for investment and advancing transformative therapies.

We invest in …

Tomorrow’s cures rely on today’s Therapeutic Enabling Technologies

Embracing the emerging convergence of biology and technology, AVANT BIO partners with visionaries at the intersection of advanced technologies and novel therapeutics. Together, we are seizing opportunities that arise from innovative companies delivering cutting-edge technologies to rapidly advance the development of game-changing therapeutics.

Capitalizing on Convergence

Advanced technologies are required to realize the promise of novel therapeutics. Innovative companies are answering that call, combining incredible new technologies with a greater understanding of biology. We recognize the immense potential in this field and are uniquely positioned to seize these opportunities.

Unlocking the Potential

Companies developing Therapeutic Enabling Technologies and Healthtech solutions offer stability and promising returns. AVANT BIO mitigates investment risks, leveraging insider access to identify high-potential companies other funds often overlook.

Forging Transformative Partnerships

AVANT BIO actively partners with visionary entrepreneurs to maximize value creation. With 40+ years of experience, we provide connections, deep expertise, and long-term guidance to bring innovative ideas to life and drive transformative therapies.

Our Portfolio

Meet the Vanguards shaping the future of life sciences with cutting-edge technologies.

Insights From Our Team

11.06.2025

PathPresenter and Primaa Partner to Advance AI in Dermatopathology

Read More

10.17.2025

AVANT VIEW Quarterly Report Q3 2025

Read More

10.16.2025

Regulatory Shockwaves: How the U.S. Is Reorienting Biopharma Policy – And What It Means for Innovation

Read More

09.26.2025

From Bottlenecks to Breakthroughs: The Future of Cell and Gene Therapy Manufacturing

Read More

09.09.2025

Nomic Bio Awards 7 Research Teams in Their First Grant Program

Read More

09.05.2025

AVANT BIO Launch Letter

Read More

07.24.2025

AVANT VIEW Quarterly Report Q2 2025

Read More

07.10.2025

Daniella Kranjac Featured in 100 Women in Finance’s Inaugural Profile Series

Read More

06.24.2025

Why We Invested: Intrepid Labs

Read More

06.24.2025

PathPresenter Achieves Key 510(k) Regulatory Milestone

Read More

06.11.2025

AVANT BIO Welcomes Ian Owens as Executive Assistant

Read More

06.01.2025

AVANT BIO Promotes Ole Henrik Bang-Andreasen to Principal

Read More

05.12.2025

AVANT BIO Leads $7M Round in Intrepid Labs to Accelerate a New Era of Drug Formulation

Read More

04.19.2025

AVANT VIEW Quarterly Report Q1 2025

Read More

03.26.2025

Nomic Partners with Novo Nordisk to Scale Proteomics for Drug Discovery

Read More

03.14.2025

PathPresenter Partners with Leading Global Cancer Center to Integrate AI Module for Oncology Research

Read More

02.11.2025

AVANT VIEW Quarterly Report Q4 2024

Read More

01.12.2025

Sebastien Latapie Promoted to Partner

Read More

01.08.2025

Advice for Founders: Pitching to Investors

Read More

11.11.2024

Why AVANT BIO Invested:  PL BioScience

Read More

11.11.2024

Funding Gap for Early Growth Stage Life Science Companies

Read More

10.27.2024

AVANT VIEW Quarterly Report Q3 2024

Read More

10.01.2024

Build Your Brand Early: A Guide for Technical Founders

Read More

09.26.2024

AVANT BIO Announces Investments in Nomic Bio, PathPresenter, and PL BioScience

Read More

09.20.2024

How is AI reshaping the Life Sciences from Drug Discovery to Biomanufacturing and Beyond

Read More

09.17.2024

AVANT BIO participates in Nomic Bio’s $42 Million, oversubscribed Series B Financing Round

Read More

09.12.2024

PathPresenter Closes $7.5M Series A Funding Led by AVANT BIO

Read More

08.22.2024

AVANT VIEW Quarterly Report Q2 2024

Read More

08.14.2024

AVANT BIO Announces Participation in PL Bioscience’s €7.8 million Series A Financing Round

Read More

06.21.2024

2024 Outlook: Therapeutic Enabling Technologies, Healthtech, TechBio

Read More

05.23.2024

AVANT VIEW Quarterly Report Q1 2024

Read More

04.11.2024

Daniella Kranjac Nominated as an INNOVATE100 Honoree

Read More

03.15.2024

SEO AICON Wrap Up

Read More

01.06.2024

Experienced Private and Public Market Investor, Peter Lee joins AVANT BIO

Read More

01.03.2024

Ole Henrik Bang-Andreasen joins AVANT BIO as an Investment Analyst

Read More

12.20.2023

AVANT BIO Emerges as a Leading Equity Firm in Life Sciences, Tech Bio, and Health Tech

Read More

Vanguards Welcome

We’re eager to connect with life science vanguards.

Penn 1
250 West 34th Street
New York, New York, 10119